Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01- Clinical Trial Optional)

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. The purpose of this Funding Opportunity Announcement (FOA) is to expand the number of genes and range of IBD-related phenotypes and physiological domains under study by means of collaborations of the IBDGC with investigators with expertise complementary to that of their own members. Proposed studies must not duplicate studies either ongoing or already completed by the IBDGC. Multi-site clinical trials will not be considered responsive to this FOA.RFA-DK-18-017
Source: NIDDK Funding Opportunities - Category: Endocrinology Source Type: funding

Related Links:

CONCLUSION: In this nationwide cohort study, the 1-year risk of pelvic sepsis following primary IPAA for ulcerative colitis increased 4-fold from 1996 to 2013. See Video Abstract at
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Original Contributions: Inflammatory Bowel Disease Source Type: research
CONCLUSION: An endoscopic decompression was required to allow a laparoscopic treatment, and a bilateral pouchopexy was needed to avoid recurrence. This standardized approach might be a good treatment option, and we are awaiting additional follow-up to determine its long-term durability. In addition to the already described risk factors (minimally invasive technique, female sex, and low BMI), an anterior positioning of the pouch mesentery might be a potential risk factor as well for pouch volvulus. However, these observations should be carefully interpreted, considering the small number of cases.
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Technical Notes Source Type: research
A new study finds that patients with autoimmune disease treated with anti- tumor necrosis factor alpha have an increased risk of developing inflammatory bowel disease.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
BACKGROUND AND AIMS: Patients with inflammatory bowel disease (IBD) have higher incidence of psychosocial disorders, including depression. As suicide is the most severe manifestation of depression, we sought to identify if patients with IBD have a higher i...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news
MONDAY, July 15, 2019 -- Patients with autoimmune diseases have an increased risk for being diagnosed with Crohn disease (CD) or ulcerative colitis (UC) while under treatment with etanercept, according to a study published online July 2 in...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
AbstractPurposeWe evaluated the recent incidence of surgery and the changing surgery trends for ulcerative colitis (UC) in Japan due to the increasing use of anti-tumor necrosis factor (TNF) agents.MethodsA questionnaire survey was performed to assess the number of surgeries, surgical indications, surgical timing, and immunosuppressive treatments before surgery between 2007 and 2017.ResultsA total of 3801 surgical cases were reported over 11  years. The prevalence of UC surgery decreased over the period studied. The rate of prednisolone (PSL) use did not change. The prevalence of both calcineurin inhibitors (CNIs) and...
Source: Surgery Today - Category: Surgery Source Type: research
ConclusionsThe prevalence of UC and CD in Japan has risen substantially over the past two  decades, and their disease burden requires further examination.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research
Mucosal Immunology, Published online: 15 July 2019; doi:10.1038/s41385-019-0189-6Anti-IL-13Rα2 therapy promotes recovery in a murine model of inflammatory bowel disease
Source: Mucosal Immunology - Category: Allergy & Immunology Authors: Source Type: research
We aim to provide guidance for medical treatment of luminal Crohn ’s disease in children.
Source: Gastroenterology - Category: Gastroenterology Authors: Tags: Clinical Practice Guideline Source Type: research
This study compared the relative efficacy and cost effectiveness of adalimumab, infliximab, and ustekinumab in patients with Crohn's disease based on data from randomized controlled trials. Methods: Data were extracted from four phase 3 clinical trials: CHARM, Watanabe et al. 2012, ACCENT I, and IM-UNITI. A network meta-analysis (NMA) compared 1-year clinical remission rates in patients who responded to treatment during an induction phase. Remission was defined as a Crohn's Disease Activity Index score
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Clinical Trials | Endocrinology | Funding | Genetics | Inflammatory Bowel Disease | Study